Torrent Pharmaceuticals Ltd.
| BSE: 500420 | Sector: Health care |
| NSE: TORNTPHARM | ISIN Code: INE685A01028 |
| BSE 00:00 | 26 May | 2900.90 |
266.35 (10.11%) |
OPEN
2750.00 |
HIGH
2931.05 |
LOW
2750.00 |
| NSE 00:00 | 26 May | 2900.95 |
266.15 (10.10%) |
OPEN
2751.00 |
HIGH
2931.15 |
LOW
2751.00 |
| OPEN | 2750.00 |
| PREVIOUS CLOSE | 2634.55 |
| VOLUME | 61292 |
| 52-Week high | 3304.45 |
| 52-Week low | 2485.00 |
| P/E | 46.80 |
| Mkt Cap.(Rs cr) | 49,089 |
| Buy Price | 0.00 |
| Buy Qty | 0.00 |
| Sell Price | 0.00 |
| Sell Qty | 0.00 |
Torrent Pharmaceuticals Ltd. (TORNTPHARM) - News Sector
-
Piramal Enterprises logs Rs 151 cr net profit in Q4, overcomes loss
8.14 pm | 26 May 2022 | Business Standard
Board recommends a dividend of Rs 33 per share, subject to shareholder's approval.
-
Sequent Scientific tanks 17% on weak Q4; stock down 70% from 52-wk high
11.34 am | 26 May 2022 | Business Standard
The company said the macro environment continues to be challenging due to volatility in costs and disruptions across supply chains.
-
Torrent Pharma rallies 9% on 1:1 bonus issue plan, dividend of Rs 23/share
9.38 am | 26 May 2022 | Business Standard
In Q4, the company posted net loss of Rs 118 crore against profit of Rs 324 crore in the year ago quarter
-
Torrent Pharma posts Rs 118 cr Q4 loss vs Rs 324 cr profit a year ago
11.37 pm | 25 May 2022 | Business Standard
The red line comes amid headwinds in EU operatopns and discontinuation of liquids business in the US; revenue, however, grows by 10%
-
Stocks to Watch: Adani Ports, Strides, Metropolis, RITES, Zee, Balrampur
7.42 am | 25 May 2022 | Business Standard
Stocks to Watch Today: Sugar and FMCG stocks likely to be in focus as govt limits sugar exports and exempts customs duty on agri cess. Apollo Hospital...
-
Divis Labs sheds 14% in two days, hits 52-week low post Q4 results
10.02 am | 24 May 2022 | Business Standard
The company has earmarked an aggressive capex of around Rs 2,000 crore over next two years in order to take a chunk of around $20 billion opportunity ...
-
Amazon, Flipkart in talks to buy stake in $1 bn diagnostic chain Metropolis
12.45 am | 21 May 2022 | Bloomberg
Metropolis runs more than 3,000 diagnostics centers as well as pathology laboratories in India and Africa
-
Board evaluating Sebi penalty of Rs 1 crore, says Fortis Healthcare
11.33 pm | 20 May 2022 | Business Standard
Market regulator SEBI slapped a fine on Fortis Healthcare subsidiaries on account of fund diversion by erstwhile promoters
-
Zydus Lifesciences Q4 net dips to 24% Rs 397 cr, revenue up 5%
11.31 pm | 20 May 2022 | Business Standard
Company says operational performance came amid geopolitical turmoil resulting in supply chain challenges and inflationary pressures
-
Dr Reddy's sees sharpest intra-day rally since Sept 2020; stock surges 8%
2.33 pm | 20 May 2022 | Business Standard
The stock gained 9 per cent in two days after the pharma company reported better-than-expected revenue growth in March quarter (Q4FY22).
-
Dr Reddy's Labs Q4 PAT falls 76% on pricing pressure, low export benefit
1.08 am | 20 May 2022 | Business Standard
Dr Reddy's Q4 results: The revenue was up 15% to Rs 5,437 crore for the quarter under review
-
Dr Reddy's plans new brands in Russia, says no issue with funds in country
12.55 am | 20 May 2022 | Business Standard
The company's Russian revenue was at Rs 686 crore for Q4FY22, a year-on-year growth of 70%.
-
Lupin slips 9%, hits 2-year low on disappointing March quarter results
9.39 am | 19 May 2022 | Business Standard
Lupin's performance was skewed on revenues front amid US and India posting lower than expected sales while RoW and South Africa saw better than antici...
-
How Prathap Chandra Reddy propelled Apollo Hospitals into a new orbit
9.35 pm | 18 May 2022 | Business Standard
The struggle that he went through in setting up a private health care facility in the India of the 1980s is part of folklore
-
We aim to test 500,000 patients a day in 5 years: Dr Lal PathLabs CMD
9.25 pm | 18 May 2022 | Business Standard
Dr Lal PathLabs is India's largest diagnostic services player by revenue, with 289 laboratories across the country
-
Caring for patients runs in our DNA, say Cipla's Samina Hamied, Umang Vohra
9.22 pm | 18 May 2022 | Business Standard
'Cipla has so many capabilities that for anything we need to do, we say we can do it'
-
Rejuvenating Cipla: After global expansion, acquisitions on cards
9.18 pm | 18 May 2022 | Business Standard
Having consolidated its presence across geographies, the pharma major is looking at acquisitions
-
Dr Reddy's Q4 PAT may rise 28% YoY; margins likely to fall, say analysts
3.16 pm | 18 May 2022 | Business Standard
The pharmaceutical giant may witness some impact due to its large exposure of the business to Russia, and CIS regions.
-
Dr Lal Pathlabs slips 6%, hits 52-week low post muted Q4 results
9.52 am | 18 May 2022 | Business Standard
In Q4FY22, normalised earnings before interest, taxes, depreciation, and amortization (EBITDA) margins contracted 630 bps to 19.4 per cent from 25.7 p...
-
Dr Lal Pathlabs Q4 consolidated PAT dips 27% to Rs 62 cr, stock sheds 1%
1.47 am | 18 May 2022 | Business Standard
Operating revenue rose 12.7% during the quarter to Rs 485.5 cr; Covid-19 and allied segments added roughly 13.6% to Q4 top line
Quick Links for Torrent Pharmaceuticals:
-
News
Announcements Brokerage Reports Business Earnings Sector -
Corporate Action
AGM Board Meetings Bonus Dividends EGM Rights Split -
INFORMATION
Bulk Deals Company History MF Holding Listing Info Locations Shareholding -
Financials
Financial Overview Balance Sheet Profit & Loss Cash Flow Ratios Quarterly Results Half Yearly Results Nine Monthly Results Yearly Results -
Annual Report
Auditors Report Chairman's Speech Company Management Directors' Report Finished Goods Raw Materials -
Peer Comparison
Competition Market Cap Price Price Performance Net Sales Net Profit Total Assets Historical Prices
